Taladegib (ENV-101)
Idiopathic Pulmonary Fibrosis (IPF)
Phase 2bActive
Key Facts
About Endeavor BioMedicines
Endeavor BioMedicines is a private, clinical-stage biotech advancing taladegib (ENV-101), a Hedgehog signaling pathway inhibitor, for the treatment of idiopathic pulmonary fibrosis (IPF). The company has generated promising Phase 2a data showing improved lung function and potential disease reversal, leading to the receipt of PRIME designation from the European Medicines Agency in late 2025. Endeavor is now advancing a Phase 2b trial (WHISTLE-PF), with enrollment completion targeted for the first half of 2026, positioning the asset as a potential disease-modifying therapy in a high-need area.
View full company profileTherapeutic Areas
Other Idiopathic Pulmonary Fibrosis (IPF) Drugs
| Drug | Company | Phase |
|---|---|---|
| OATD-01 | Molecure | Phase II |
| FP-020 (BMS-986235) | Foresee Pharmaceuticals | Phase 2 |
| Buloxibutid (C21) | Vicore Pharma | Phase 2b |
| AP02 | Avalyn Pharmaceuticals | Phase 2 |
| Gento-Fibrose Pulmonaire Program | Genoscience Pharma | Preclinical |
| SM001 (alidornase/Tigerase) | SarcoMed USA | Research |
| NLM-001 | Nelum Pharma | Phase 1 |
| GNS-3545 (ROCK2 Inhibitor) | Genosco | Phase 1 |
| TG2 Inhibitor Program | Isterian Biotech | Preclinical |
| CAL101 | Calluna Pharma | Phase 2 |
| NVP-13 | Velvio | Pre-clinical |
| LASN01 | Lassen Therapeutics | Preclinical |